Comparative Pharmacology
Head-to-head clinical analysis: AMCILL versus AMPICILLIN AND SULBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMCILL versus AMPICILLIN AND SULBACTAM.
AMCILL vs AMPICILLIN AND SULBACTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
250-500 mg orally every 8 hours or 500 mg every 12 hours; for severe infections, up to 1 g every 6 hours intravenously.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
None Documented
None Documented
1-1.5 hours in normal renal function; prolonged to 7-10 hours in anuria.
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
Renal: 60-80% unchanged; biliary: less than 10%; fecal: small amount.
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic